Stock Events

Stock Events

SAB Biotherapeutics 

$3.88
6
+$0.01+0.26% Today

Statistics

Day High
3.97
Day Low
3.84
52W High
6.6
52W Low
1
Volume
82,576
Avg. Volume
589,449
Mkt Cap
30.82M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

8MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-1.19
-0.86
-0.54
-0.21
Expected EPS
-0.212475
Actual EPS
N/A

Financials

-19,208.77%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
114,000Revenue
-21.9MNet Income

Analyst Ratings

$10.75Average Price Target
The highest estimate is 15.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SABS. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals competes in the development of monoclonal antibodies, a space SAB Biotherapeutics is also focusing on, particularly in immunotherapy treatments.
Adma Biologics
ADMA
Mkt Cap3.69B
ADMA Biologics is involved in the development, manufacturing, and marketing of specialty plasma-derived biologics, directly competing with SAB's platform for therapeutic proteins.
Novavax
NVAX
Mkt Cap1.36B
Novavax is a competitor due to its work on vaccines, including those for infectious diseases, a key area of focus for SAB Biotherapeutics.
Moderna
MRNA
Mkt Cap10.61B
Moderna is known for its mRNA technology but is expanding into other areas of infectious disease treatment and vaccine development, making it a competitor.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech competes in the space of developing novel therapies, including mRNA-based vaccines, which could overlap with SAB's infectious disease focus.
Pfizer
PFE
Mkt Cap140.15B
Pfizer, with its broad range of vaccines and therapeutic agents, competes across several areas, including those targeted by SAB Biotherapeutics.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline, with its extensive vaccine and therapeutic portfolio, competes in the immunotherapy and infectious disease space.
Sanofi
SNY
Mkt Cap124.45B
Sanofi operates in similar therapeutic areas, including vaccines and immune response treatments, making it a competitor.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the development of vaccines and treatments for infectious diseases.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca is involved in the research and development of vaccines and treatments for various diseases, competing with SAB Biotherapeutics in the immunotherapy space.

About

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
Show more...
CEO
Mr. Samuel J. Reich
Employees
63
Country
US
ISIN
US78397T2024

Listings

XNAS
US
SABSW
XNAS
US
SABS
BOATS
BOATS
SABS.BOATS

0 Comments

Share your thoughts

FAQ

What is SAB Biotherapeutics stock price today?▼
The current price of SABS is $3.88 USD — it has increased by +0.26% in the past 24 hours. Watch SAB Biotherapeutics stock price performance more closely on the chart.
What is SAB Biotherapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange SAB Biotherapeutics stocks are traded under the ticker SABS.
Is SAB Biotherapeutics stock price growing?▼
SABS stock has risen by +1.31% compared to the previous week, the month change is a -4.67% fall, over the last year SAB Biotherapeutics has showed a +210.4% increase.
What is SAB Biotherapeutics market cap?▼
Today SAB Biotherapeutics has the market capitalization of 30.82M
When is the next SAB Biotherapeutics earnings date?▼
SAB Biotherapeutics is going to release the next earnings report on May 08, 2026.
What were SAB Biotherapeutics earnings last quarter?▼
SABS earnings for the last quarter are -0.21 USD per share, whereas the estimation was -0.22 USD resulting in a +4.57% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is SAB Biotherapeutics revenue for the last year?▼
SAB Biotherapeutics revenue for the last year amounts to 114,000 USD.
What is SAB Biotherapeutics net income for the last year?▼
SABS net income for the last year is -21.9M USD.
How many employees does SAB Biotherapeutics have?▼
As of April 02, 2026, the company has 63 employees.
In which sector is SAB Biotherapeutics located?▼
SAB Biotherapeutics operates in the Health Care sector.
When did SAB Biotherapeutics complete a stock split?▼
The last stock split for SAB Biotherapeutics was on January 05, 2024 with a ratio of 1:10.
Where is SAB Biotherapeutics headquartered?▼
SAB Biotherapeutics is headquartered in Miami Beach, US.